louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00265278: Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
Official title: Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Amphetamine-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2005-12-14
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral Modafinil.

Detailed description: The primary aims of this experiment are to determine if there are significant safety interactions between oral modafinil and intravenous methamphetamine. Safety will be assessed by measuring adverse events and cardiovascular responses of heart rate (HR), blood pressure (BP), and electrocardiogram (ECG) and stroke distance (ICG).

Eligibility criteria: Inclusion Criteria:

* normotensive
* good physical and mental health
* body mass index between 18 and 30
* if female, using an acceptable method of contraception and are not pregnant
* able to give voluntary informed consent

Exclusion Criteria:

* Please contact site for further details

Primary outcomes:
measure: Cardiovascular
measure: Subjective symptoms/Mood Effects
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: U of CA, San Francisco
state: California
Study officials:
affiliation: Langley Porter Psychiatric Institute
name: Reese Jones, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03991078: Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency
Official title: Pilot Clinical Study to Evaluate the Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Size of the Uterine Fibroids
Lead sponsor: Fundación IVI
Sponsor class: OTHER
Collaborators: name: Hospital Universitario La Fe
First posted: 2019-06-19
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with uterine fidroids and hypovitaminosis D

Brief summary: Vitamin D supplementation in patients with uterine fibroids who present hypovitaminosis D to re-establish their normal serum values could stabilize the size of the uterine fibroids and thus prevent their growth or reduce their size thanks to the anti-proliferative action of Vitamin D on the myoma cells.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with at least one fibroid \> 3 cm
* With hypovitaminosis D (25(OH)D \< 30 ng/ml)
* BMI \< 30
* No hormonal treatment in the 3 months prior to the ultrasound study

Exclusion Criteria:

* Black race
* Symptomatic fibroids subsidiary to hormonal or surgical treatment
* Desire of gestation in the next 6 months
* Presence of degenerating adenomyosis or fibroids
* Treatment with sexual hormones: mifepristone, aGnRH or any other medication that may interfere with fibroids.
* History of neoplasia of gynecological origin and/or existence of uterine malformations.
* Hypercalcemia or abnormal liver or kidney function is present

Primary outcomes:
measure: volume of the uterine fibroids
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Fundacion IVI
Study officials:
affiliation: Fundación IVI
name: Antonio Pellicer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00990678: Study of Vitamin D Supplementation to Male HIV Sero-positive Patients
Official title: Study of Vitamin D Supplementation to Male HIV Sero-positive Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Seropositive
Keywords: HIV-1
humans
vitamin D
1-hydroxy-vitamin D
Rocaltrol
calcium
complementary therapies
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2009-10-07
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets):

1. Calcium
2. Calcium and 25-hydroxy-vitamin D
3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D

The endpoints are:

* Serum vitamin D
* Parathyroid hormone
* ionized calcium
* T-lymphocyte fractions (naïve, mature, Tregs)
* Osteocalcin (bone metabolism)


Eligibility criteria: Inclusion Criteria:

* male
* HIV-positive
* at least 18 years old
* receiving HiglyActiveAntiRetroviral Therapy (HAART)

Exclusion Criteria:

* hypercalcemia
* tuberculosis
* osteoporosis or other bone disease
* cancer with bone metastasis

Primary outcomes:
measure: serum-vitamin D metabolites
timeFrame: week 0
measure: serum-vitamin D metabolites
timeFrame: week 2
measure: serum-vitamin D metabolites
timeFrame: week 4
measure: serum-vitamin D metabolites
timeFrame: week 8
measure: serum-vitamin D metabolites
timeFrame: week 12
measure: serum-vitamin D metabolites
timeFrame: week 16
Secondary outcomes:
measure: T-lymphocyte fractions Parathyroid hormone ionized calcium
timeFrame: week 0
measure: T-lymphocyte fractions Parathyroid hormone ionized calcium
timeFrame: week 2
measure: T-lymphocyte fractions Parathyroid hormone ionized calcium
timeFrame: week 4
measure: T-lymphocyte fractions Parathyroid hormone ionized calcium
timeFrame: week 8
measure: T-lymphocyte fractions Parathyroid hormone ionized calcium
timeFrame: week 12
measure: T-lymphocyte fractions Parathyroid hormone ionized calcium
timeFrame: week 16
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Dept. of endocrinology, Hvidovre Hospital
Study officials:
affiliation: Dept. of Endocrinology, Hvidovre Hospital
name: Ulrich C Bang, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bang U, Kolte L, Hitz M, Dam Nielsen S, Schierbeck LL, Andersen O, Haugaard SB, Mathiesen L, Benfield T, Jensen JE. Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials. 2012 May-Jun;13(3):162-70. doi: 10.1310/hct1303-162.
Clinical trial NCT04795778: The Validity and Reliability of FIT-HaNSA in Breast Cancer Patients
Official title: The Validity and Reliability of FIT-HaNSA (Functional Impairment Test-Hand and Neck/Shoulder/Arm) in Breast Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
FIT-HaNSA
Upper Extremity Dysfunction
Keywords: Breast Cancer
FIT-HaNSA
Upper Extremity Dysfunction
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2021-03-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Breast cancer patients referred to physiotherapy and rehabilitation from Gazi University hospital

Brief summary: Breast cancer is the most common type of cancer among women and covers 25% of all cancers. After mastectomy and reconstruction, many patients develop various upper extremity complications such as joint movement limitation, pain, lymphedema, and axillary cord. Because of such upper extremity problems, evaluation and treatment of upper extremity functions are important. Upper extremity functions are generally evaluated with questionnaires filled out by the patients themselves and which reflect their own perspectives subjectively. However, these questionnaires cannot reflect the observations and evaluations of the clinicians. Performance tests are important for clinicians to make decisions.

With this study, we want to examine the usability of the FIT-HaNSA test in the evaluation of upper extremity functions in patients with breast cancer. Our hypothesis; The FıtHaNSA test is successful in evaluating the upper extremity function in patients with breast cancer.


Eligibility criteria: Inclusion Criteria:

* Those whose treatments for breast cancer have been completed 18 years and over

Exclusion Criteria:

* Have a history of upper extremity surgery, excluding breast cancer surgery Have a history of upper extremity trauma Those who have orthopedic, neurological, rheumatological or cognitive impairments that may interfere with the application of the test.

Primary outcomes:
measure: FIT-HaNSA test for upper extremity performance
timeFrame: For the patient group; at least 3 months after all treatments have been completed
measure: Upper extremity disability
timeFrame: For the patient group; at least 3 months after all treatments have been completed
measure: Upper extremity functionality
timeFrame: For the patient group; at least 3 months after all treatments have been completed
measure: Shoulder disability
timeFrame: For the patient group; at least 3 months after all treatments have been completed
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Inci Ayas
Study officials:
affiliation: Gazi University
name: inci ayas
role: STUDY_DIRECTOR
References:
Clinical trial NCT06466278: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
Official title: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Aortic Valve Stenosis
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
First posted: 2024-06-20
Enrollment: 110
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study invastigates the effect of icosapent ethyl in patients with aortic valve stenosis.


Eligibility criteria: Inclusion Criteria:

1. Age \> 50 years
2. Mild to moderate AVS

Exclusion Criteria:

1. Bicuspid aortic valve
2. History of chest radiotherapy
3. History of rheumatic fever
4. Moderate to severe renal failure, defined as eGFR \< 30 ml/min
5. Hyperparathyroidism
6. Paget's disease
7. Diagnosis of (active) malignancy in last 5 years
8. Anticipated or planned aortic valve surgery in the next 6 months
9. Life expectancy \<2 years
10. Chronic atrial fibrillation
11. Use of anticoagulant medication or dual antiplatelet therapy
12. Known hypersensitivity to fish and/or shellfish
13. Known hypersensitivity to soya
14. Malabsorption syndrome and/or chronic diarrhea
15. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control \[such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (condoms)\] to avoid pregnancy for the entire study.
16. Women who are pregnant or breastfeeding
17. Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
18. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study

Primary outcomes:
measure: Change in aortic valve calcium (AVC) score
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Academic Medical Center
Study officials:
References:
Clinical trial NCT03183778: Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
Official title: Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Kidney Diseases
Hyperkalemia
Keywords: Chronic kidney disease, stages 3B-4
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2017-06-12
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this proof-of-concept controlled-feeding study is to determine whether patiromer (Veltassa®, Relypsa, Inc., Redwood City, CA) can be used to maintain normal serum potassium concentrations in chronic kidney disease (CKD) patients who are transitioned to a plant-rich diet.


Eligibility criteria: Inclusion Criteria:

* Stages 3B-4 CKD (estimated glomerular filtration rate (eGFR) of 15-44 mL/min/1.73m2, not treated with dialysis)
* No prior treatment with patiromer
* Mild hyperkalemia (potassium 5.1 to \<6.5 mEq/L) on one of the last two blood tests
* No prior episodes of moderate-severe hyperkalemia (potassium ≥6.5 mEq/L) in the past 6 months
* Deemed appropriate for the intervention by the patient's nephrologist, considering the patient's prognosis, cognition and pending treatments (e.g., dialysis)

Exclusion Criteria:

* Change in medications that alter potassium homeostasis (e.g., RAAS inhibitors, diuretics, β-blockers) in the last month
* Diagnosed with bowel diseases or syndromes (e.g., bowel obstruction, major GI surgery, short-bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, chronic diarrhea)
* Dietary restrictions (e.g., allergies) or otherwise unable/unwilling to adhere to study diets (excludes dietary restrictions on high-potassium foods)
* Pregnant (females) or planning to become pregnant (males and females) during the study

Primary outcomes:
measure: Change in Fasting Serum Potassium Concentrations
timeFrame: Baseline, Week 2
measure: Change in Fasting Serum Potassium Concentrations
timeFrame: Baseline, Week 4
measure: Change in Systolic Blood Pressure (SBP)
timeFrame: Baseline, Week 2
measure: Change in Systolic Blood Pressure (SBP)
timeFrame: Baseline, Week 4
measure: Change in Diastolic Blood Pressure (DBP)
timeFrame: Baseline, Week 2
measure: Change in Diastolic Blood Pressure (DBP)
timeFrame: Baseline, Week 4
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: David Goldfarb, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01991678: A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
Official title: An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Hepatic Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
Lead sponsor: Nektar Therapeutics
Sponsor class: INDUSTRY
First posted: 2013-11-25
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.

Detailed description: Safety and PK data from patients with mild, moderate, or severe hepatic impairment will be compared with a control group consisting of patients with normal hepatic function.

Eligibility criteria: Inclusion Criteria:

* Relapsed or progressive advanced solid tumor malignancies
* Measurable or non-measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Life expectancy greater than 3 months
* Resolution of all acute toxic effects of prior chemotherapy, and other cancer treatments
* Adequate bone morrow and kidney function
* No signs of decompensated liver cirrhosis or ascites requiring therapeutic paracentesis
* Agree to use adequate contraception

Exclusion Criteria:

* Previous chemotherapy, immunotherapy, chemo-embolization, targeted therapy or investigational agent for malignancy within 4 weeks prior to day 1
* Cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks prior to day 1
* Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days prior to day 1
* UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1\*28) or TA 8 in either one or both alleles (hetero- or homozygous for UGT1A1\*37)
* Major surgery within 4 weeks prior to day 1
* Undergone a liver or other organ transplant
* Concurrent treatment with other anti-cancer therapy
* Untreated central nervous system metastases
* Ongoing or active infection
* Chronic or acute GI disorders resulting in diarrhea
* Pregnancy or lactation

Primary outcomes:
measure: Pharmacokinetics (PK) of NKTR-102 and its metabolites
timeFrame: Day 1 through Day 42
Secondary outcomes:
measure: Safety and tolerability of NKTR-102
timeFrame: Day 1 through Day 42
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC/LA County
state: California
city: San Francisco
country: United States
facility: UCSF Helen Diller Family Comprehensive Cancer Center
state: California
city: Cleveland
country: United States
facility: University Hospitals Case-Medical Center Seidman Cancer Center
state: Ohio
Study officials:
affiliation: Nektar Therapeutics
name: Ivan Gergel, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01246778: Sunitinib and Atrial Trabeculae Contractility
Official title: The Influence of Sunitinib on Contractility of Human Atrial Trabeculae
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiotoxicity
Ischemia
Heart Failure
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2010-11-23
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 44 patients undergoing cardiac surgery with extracorporal circulation

Brief summary: Rationale:

Recently, sunitinib (a tyrosine kinase inhibitor that is used for treatment of metastatic renal carcinoma and gastrointestinal stroma tumors) has been associated with development of heart failure, possibly by off-target inhibition of AMP-protein kinase. The investigators hypothesize that sunitinib reduces the contractile ability of myocardium and the tolerance against ischemia-reperfusion and that activators of AMP-protein kinase such as atorvastatin and AICAR reverse this unwanted effect of sunitinib.

Objectives:

The primary objective of the study is to investigate the effect of sunitinib on ex-vivo atrial contractile force in absence and presence of ischemia-reperfusion.

A secondary objective is to explore if atorvastatin or AICAR prevent sunitinib-induced deterioration of contractile function of human atrial trabeculas. Study design: Lab

Detailed description: Study population: 44 (+22) patients undergoing CABG cardiac surgery with extracorporal circulation Intervention (if applicable): none (pharmacological interventions will only be performed ex-vivo in isolated atrial tissue) Main study parameters/endpoints The developed force in ex vivo atrial trabeculas during standardized stimulation.

Eligibility criteria: Inclusion Criteria:

* Cardiac surgery with extracorporal circulation

Exclusion Criteria:

* Use of oral antiarrhythmics
* theophylline use
* Use of sulfonylureas
* Atrial arrythmias
* Right ventricular failure

Primary outcomes:
measure: Force
timeFrame: 200 minutes
Secondary outcomes:
measure: Speed
timeFrame: 200 minutes
measure: Maximal Speed
timeFrame: 210 minutes
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Centre
Study officials:
affiliation: Radboud University Medical Center
name: G. A. Rongen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01105078: Optimal Flow Rate During Cardiopulmonary Bypass
Official title: Optimal Flow Rate During Cardiopulmonary Bypass
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tissue Perfusion
Keywords: cardiopulmonary bypass flow rate outcome tissue perfusion oxygenation l/min/m2
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2010-04-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Regardless of the development of cardiac surgery techniques and technologies, the question of an optimal extracorporeal circulation is still unanswered. There are globally accepted standards of perfusion, however, keep many of these procedures was not evidence-based review.

Generally accepted are flow rates during cardiopulmonary bypasses of 2.5 L/min/m2. This target was derived from the physiological conditions, but they are not the result of an adapted adjustment to the fundamentally non-physiological processes during extracorporeal circulation. Among other things, an increased metabolic demand during re-perfusion is not taken into account.

An increasing and optimizing of the standard flow rate of 0.5 L/min/m2 should be the aim of this investigation. Under optimal perfusion, the investigators are maintaining the microcirculation and organ protection in receipt of endothelial function and oxygen transport.


Eligibility criteria: Inclusion Criteria:

* Extracorporeal circulation
* Age \> 18
* Written consent

Exclusion Criteria:

* Emergency cases

Primary outcomes:
measure: Microcirulation
timeFrame: intraooperative
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt am Main
country: Germany
facility: Johann Wolfgang Goethe University Hospital
Study officials:
References:
Clinical trial NCT05274178: Effect of Hearing Aid Labeling on Speech Understanding Measures
Official title: Effect of Hearing Aid Labeling on Speech Understanding Measures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
First posted: 2022-03-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: A single group of participants will be involved in this study. All participants will be evaluated with both hearing devices.
Primary purpose: TREATMENT

Brief summary: New and experienced hearing aid users will be fit with two hearing devices. One will be labeled as an OTC (Over-The-Counter) device, the other will be labeled as a Prescriptive (i.e. professionally fit) device. Both devices will be generically programmed for a mild to moderate hearing loss. An objective speech in noise test will be completed with both devices.


Eligibility criteria: Inclusion Criteria:

* Adults age 18 or older with bilateral mild to moderate hearing loss
* Experienced users must have at least 6 months Hearing Aid experience
* New users must have no prior hearing aid experience, defined as never owning their own devices

Exclusion Criteria:

* Self-reported ear related pathology (otorrhea w/in 90 days, dizziness, sudden hearing loss or worsening of hearing w/in 90 days, otalgia)
* Visible deformity of the ear
* Chronic, severe tinnitus
* Unilateral hearing loss
* Cognitive impairment

Primary outcomes:
measure: Quick Speech in Noise Test (QuickSIN)
timeFrame: Day 1 of 1 day study
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Sonova US
state: Illinois
Study officials:
References: